In a remarkable turn of events, the Global Non-alcoholic Steatohepatitis Drugs Pipeline Industry is poised for an extraordinary valuation of US$ 0.27 Billion by the end of 2023, with expectations to soar at an impressive CAGR of 33.3% from 2025 to 2033. The latest study conducted by Future Market Insights reveals that mid-stage products (phase II) are at the forefront, commanding a substantial 66.7% market share in 2022.
This unprecedented growth trajectory signifies a paradigm shift in the pharmaceutical landscape, as the NASH drugs pipeline market emerges as a focal point for innovation and investment. The forecasted valuation of approximately US$ 51.36 Billion by 2033 is a testament to the industry’s relentless pursuit of groundbreaking solutions for Non-Alcoholic Steatohepatitis.
Request a Sample of this Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-6719
Non-alcoholic steatohepatitis (NASH) is a rare disease of liver characterized by buildup of fat in the liver. Prevalence of Nonalcoholic steatohepatitis is increasing parallel to the prevalence of obesity across the globe. Non-alcoholic steatohepatitis is caused by insulin resistance and the accumulation of toxic lipid metabolites of triglycerides.
Several new drugs are being evaluated in clinical trials for the treatment of non-alcoholic steatohepatitis, however, there is no approved drugs available till now. Several molecules are about to complete phase 2 clinical trial and are entering in the most complex phase 3. According to Covance, Inc. survey NASH is the most common liver disease among obesity patients and affects over 60% of the obese population.
Cirrhosis due to non-alcoholic steatohepatitis is the third most common cause of liver transplantation in the U.S. The global burden of NASH is increasing every year and there is an urgent need to develop effective treatment for non-alcoholic steatohepatitis. There is a rich pipeline of drugs being studied for non-alcoholic steatohepatitis treatment with huge range of products with different mechanism.
Global Non-alcoholic Steatohepatitis Drugs Pipeline Industry: Drivers and Restraints
Growing pace of research activities and stimulation of funding are the factors supporting the growth of pipeline activities in non-alcoholic steatohepatitis treatment. More number of clinical candidates are advancing to late stages of development, which are expected to be launched in the global market within the course of next 8 years.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-6719
For instance, currently four drugs are being studied in phase 3 clinical trial, with wide range of mechanisms. Intercept Pharmaceuticals is evaluating its lead molecule- farnesoid X receptor acting agent in metacentric phase 3 trial. Genfit’s Elafibranor has reached phase 3, which is peroxisome proliferator-activated receptor alpha/delta agonist. Two more drugs in phase 3 trial include Tobira Therapeutics’ Cenicriviroc and Gilead’s selonsertib. Failure of these drugs in late stage would cause huge financial losses to the sponsors, which is the biggest risk factor for non-alcoholic steatohepatitis drugs pipeline.
Non-alcoholic Steatohepatitis Drugs Pipeline Industry: Regional Overview
Geographically, the global non-alcoholic steatohepatitis drugs pipeline report is divided into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominates the global clinical trial activities in non-alcoholic steatohepatitis treatment with over 200 active clinical trials being carried out in the U.S. and Canada.
Western Europe witnesses the second largest magnitude of clinical activities in non-alcoholic steatohepatitis treatment with over 120 active clinical trials. Japan shows low level of research activities in non-alcoholic steatohepatitis.
Global Non-alcoholic Steatohepatitis Drugs Pipeline Industry: Key Players
Some of the key players having nonalcoholic steatohepatitis drugs in their pipeline include Tobira Therapeutics, Inc., Genfit SA, Intercept Pharmaceuticals Inc., Gilead Sciences, Inc., Bristol-Mayers Squibb and Company, Merck KGaA, NGM Biopharmaceuticals, Galectin Therapeutics Inc., Madaus Inc. etc. among others.
Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/askus/rep-gb-6719
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Global Non-alcoholic Steatohepatitis Drugs Pipeline Industry: Segmentation
The nonalcoholic steatohepatitis drugs pipeline products are classified based on drug class, mechanism, phases and geography
Based on drug class, nonalcoholic steatohepatitis pipeline drugs are classified in to the following
- Drugs Targeting Metabolic Homeostasis
- Drugs Acting on Insulin Resistance
- Drugs to Prevent and Treat Inflammation
- Drugs Preventing Oxidative Stress or Fibrosis
Based on mechanism, nonalcoholic steatohepatitis pipeline drugs are classified in to the following:
- Farnesoid X receptor Modulation
- Peroxisome proliferator-activated receptor agonist
- C chemokine receptor Antagonist
- Apoptosis signal-regulated kinase-1 inhibitor
- Oral acetyl-CoA carboxylase (ACC) inhibitor
- Fibroblast growth factor 21 (FGF 21) inhibitor
- Others
Based on the development phase, nonalcoholic steatohepatitis pipeline drugs are classified into the following
- Discovery
- Preclinical
- Phase 1 CT
- Phase 2 CT
- Phase 3 CT
- IND/CTA Filed
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https: www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
